ELI LILLY & CO (LLY)       342.57  -1.58 (-0.46%)

342.57  -1.58 (-0.46%)

US5324571083 - Common Stock - Premarket: 335.8 -6.77 (-1.98%)


Fundamental Rating

5

Overall LLY gets a fundamental rating of 5 out of 10. We evaluated LLY against 261 industry peers in the Pharmaceuticals industry. While LLY has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, LLY is valued expensive at the moment.




Profitability

Profitability Rating

7

LLY's Return On Equity of 59.91% is amongst the best returns of the industry. LLY outperforms 85% of its industry peers. The industry average return on equity is 20.44%.
LLY has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for LLY.

LLY has a Return On Assets of 12.71%. This is comparable to the industry average of 9.69%.
LLY's Profit Margin of 20.63% is in line with the rest of the industry. The industry average Profit Margin is 18.55%.
VS Industry

ROA (12.71%) VS Industry: 60% outperformed.

0.97
111.39

ROE (59.91%) VS Industry: 85% outperformed.

1.97
178.77

Profit Margin (20.63%) VS Industry: 60% outperformed.

2.50
1,952.78

Valuation

Valuation Rating

0

The Price/Earnings Ratio is 40.35, which means the current valuation is very expensive for LLY.
Compared to an average industry Price/Earning Ratio of 13.58, LLY is valued more expensive than its industry peers. On top of this 93% of the companies listed in the same industry are cheaper than LLY!
With a Forward Price/Earnings Ratio of 37.08, LLY is valued very expensively.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates LLY does not grow enough to justify the current Price/Earnings ratio.

With a price book ratio of 33.58, LLY is valued rather expensively.
Compared to an average industry price book ratio of 1.50, LLY is valued more expensive than its industry peers. 98% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of LLY to the average industry ratio of 11.35, LLY is valued more expensive than its industry peers. 88% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (40.35) VS Industry: 7% outperformed.

112.77
0.02

Price/Book (33.58) VS Industry: 2% outperformed.

540.61
0.13

Enterprise Value/ EBITDA (34.57) VS Industry: 12% outperformed.

258.44
0.25

Growth

Growth Rating

6

LLY shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 18.34% yearly.
Based on estimates for the next 5 years, LLY will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.90% on average per year.
LLY is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 11.67% yearly.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

LLY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.71%.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
LLY shows a small growth in Revenue. In the last year, the Revenue has grown by 5.34%.
The Revenue has been growing slightly by 5.94% on average over the past 5 years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS18.34% 13.69% 0.71% -3.85% 6.35% 14.91% 17.9%
Revenue5.94% 9.63% 5.34% 2.09% 3.66% 8.11% 11.67%

Health

Health Rating

6

LLY has an Altman-Z score of 6.98. This indicates that LLY is financially healthy and little risk of bankruptcy at the moment.
LLY has one of the better Altman-Z scores in its industry. It is much better than the industry average of -0.37. LLY has a better score than 82% of its industry peers.
The Piotroski-F score of LLY is 8.00. This is a very strong score and indicates great health and profitability for LLY.
LLY has a Current Ratio of 1.13. This is a normal value and indicates that LLY is financially healthy and should not expect problems in meeting its short term obligations.

When comparing the Current Ratio of LLY to the average industry Current Ratio of 3.49, LLY is less able to pay its short term obligations than its industry peers. 85% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.88 indicates that LLY may have some problems paying its short term obligations.
When comparing the Quick Ratio of LLY to the average industry Current Ratio of 2.84, LLY is less able to pay its short term obligations than its industry peers. 84% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, LLY is requires more financing than its industry peers. 91% of its industry peers have a better Debt to Equity Ratio.
VS Industry

Debt/Equity (1.4) VS Industry: 9% outperformed.

59.36
0.00

Quick Ratio (0.88) VS Industry: 16% outperformed.

-2.73
76.82

Current Ratio (1.13) VS Industry: 15% outperformed.

0.10
76.82

Altman-Z (6.98) VS Industry: 82% outperformed.

-244.28
84.57

Dividend

Dividend Rating

4

The dividend of LLY is nicely growing with an annual growth rate of 14.75%!
LLY has paid a dividend for at least 10 years, which is a reliable track record.
LLY has a Yearly Dividend Yield of 1.31%.
LLY pays out 56.76% of its income as dividend. This is a bit on the high side, but may be sustainable.

With a Dividend Yield of 1.31, LLY pays less dividend than the industry average, which is at 2.85. 83% of the companies listed in the same industry pay a better dividend than LLY!
Compared to an average S&P500 Dividend Yield of 2.41, LLY's dividend is way lower than the S&P500 average.
The dividend of LLY is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
VS Industry

Dividend Yield (1.31%) VS Industry: 17% outperformed.

0.71
7.11

ELI LILLY & CO342.57

NYSE:LLY (2/1/2023, 7:25:37 PM)-1.58 (-0.46%)

Premarket: 335.8 -6.77 (-1.98%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 02-02 2023-02-02
Inst Owners 80.23% Inst Owner Change -0.1%
Ins Owners 10.56% Ins Owner Change -0.89%
Market Cap 338.16B Analysts 80
Price Target 397.31 (15.98%)

Dividend
Dividend Yield 1.31% Dividend Growth 14.75%
DP 56.76% Ex-Date 02-14 2023-02-14 (1.13)

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) -12.22%
Min EPS beat(2) -26.71% Max EPS beat(2) 2.27%
EPS beat(4) 3 Avg EPS beat(4) -1.52%
Min EPS beat(4) -26.71% Max EPS beat(4) 18.07%
Revenue beat(2) N/A Avg Revenue beat(2) -3.2%
Min Revenue beat(2) -6.12% Max Revenue beat(2) -0.28%
Revenue beat(4) 2 Avg Revenue beat(4) 0.21%
Min Revenue beat(4) -6.12% Max Revenue beat(4) 4.79%
PT rev (1m) 0.45% PT rev (3m) 11.54%
EPS NQ rev (1m) 0% EPS NQ rev (3m) -9.85%
EPS NY rev (1m) 0% EPS NY rev (3m) -2.25%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) -2.32%
Revenue NY rev (1m) 0% Revenue NY rev (3m) -0.5%

Valuation
Industry RankSector Rank
PE 40.35
Fwd PE 37.08
P/S 11.57
P/FCF 63.34
P/OCF 44.14
P/B 33.58
P/tB N/A
EV/EBITDA 34.57
EPS(TTM) 8.49 EY 2.48%
EPS(NY) 9.24 Fwd EY 2.7%
FCF(TTM) 5.41 FCFY 1.58%
OCF(TTM) 7.76 OCFY 2.27%
SpS 29.62 BVpS 10.2
TBVpS -0.96 PEG (NY) N/A
PEG (5Y) 2.2

Profitability
Industry RankSector Rank
ROA 12.71%
ROE 59.91%
ROIC 23.74%
ROICexc 25.98%
ROICexgc 41.83%
OM 29.29%
PM 20.63%
GM 75.61%
ROICexgc(3y) 33.07% ROICexcg growth 3Y 17.44%
ROICexcg growth 5Y 9.5% ROICexc(3y) 20.45%
ROICexc growth 3Y 3.15% ROICexc growth 5Y 8.56%
OM growth 3Y -0.33% OM growth 5Y 7.88%
PM growth 3Y 9.44% PM growth 5Y 8.85%
GM growth 3Y -1.75% GM growth 5Y 0.22%
F-Score 8 Asset Turnover 0.62

Health
Industry RankSector Rank
Debt/Equity 1.4
Debt/FCF 2.98
Debt/EBITDA 1.56
Cap/Depr 145.78%
Profit Quality 88.49%
Current Ratio 1.13
Quick Ratio 0.88
Altman-Z 6.98
F-Score 8 WACC 8.41%
ROIC/WACC 4.97 Cap/Depr(3y) 128.04%
Cap/Depr(5y) 141.95% Profit Quality(3y) 70.19%
Profit Quality(5y) N/A

Growth
EPS 1Y 0.71% EPS 3Y 13.69%
EPS 5Y 18.34% EPS growth Q2Q 2.06%
EPS Next Y -3.85% EPS Next 2Y 6.35%
EPS Next 3Y 14.91% EPS Next 5Y 17.9%
Revenue growth 1Y 5.34% Revenue growth 3Y 9.63%
Revenue growth 5Y 5.94% Revenue growth Q2Q 2.49%
Revenue Next Year 2.09% Revenue Next 2Y 3.66%
Revenue Next 3Y 8.11% Revenue Next 5Y 11.67%
EBIT growth 1Y 14.52% EBIT growth 3Y 9.27%
EBIT growth 5Y 14.28% EBIT Next Year 10.09%
EBIT Next 3Y 19.49% EBIT Next 5Y 20.67%
FCF growth 1Y 4.43% FCF growth 3Y 29.06%
FCF growth 5Y 7.46% OCF growth 1Y 15.24%
OCF growth 3Y 9.54% OCF growth 5Y 8.4%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA